Monte Rosa Therapeutics, Inc.
GLUE- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001826457
In the last 90 days, Monte Rosa Therapeutics, Inc. insiders filed 0 open-market purchases and 4 sales; 192 institutions reported holding it in 13F filings for Q2 2026, worth $2.24B in total; Duquesne Family Office is the only superinvestor holding it.
13F holders, Q4 2024
Institutional positions in Monte Rosa Therapeutics, Inc. as of Dec 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 105
- +24 vs. Q3 2024
- Shares held
- 61.0M
- +11.2M (+22.6%) vs. Q3 2024
- Total value
- $423.3M
- +$159.6M (+60.5%) vs. Q3 2024
- New holders
- 35
- 36 more added
- Sold out
- 11
- 17 more reduced
Compare with Q3 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting GLUE on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 192 | $2.24B |
| Q1 2026 | 191 | $1.43B |
| Q4 2025 | 161 | $1.01B |
| Q3 2025 | 129 | $444.9M |
| Q2 2025 | 116 | $280.6M |
| Q1 2025 | 106 | $276.2M |
| Q4 2024 | 105 | $423.3M |
| Q3 2024 | 81 | $263.7M |
| Q2 2024 | 75 | $171.7M |
| Q1 2024 | 68 | $281.3M |
| Q4 2023 | 71 | $226.6M |
| Q3 2023 | 71 | $201.4M |
| Q2 2023 | 68 | $272.3M |
| Q1 2023 | 69 | $309.8M |
| Q4 2022 | 66 | $313.8M |
| Q3 2022 | 70 | $328.8M |
| Q2 2022 | 57 | $375.0M |
| Q1 2022 | 52 | $559.9M |
| Q4 2021 | 53 | $742.0M |
| Q3 2021 | 56 | $759.4M |
| Q2 2021 | 48 | $705.1M |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2024
Shares, value and share of portfolio for each institution holding Monte Rosa Therapeutics, Inc.; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Baker Bros. Advisors LP | 4,916,095 | $34.1M | 0.36% | 00.0% | Unchanged |
| FMR LLC | 5,548,448 | $38.5M | 0.00% | +447,035+8.8% | Added |
| Versant Venture Management, LLC | 5,652,922 | $39.2M | 45.22% | +5,652,922 | New |
| Price T Rowe Associates Inc | 7,116,637 | $49.4M | 0.01% | +515,496+7.8% | Added |
| NEA Management Company, LLC | 7,692,298 | $53.4M | 3.01% | 00.0% | Unchanged |
| ExodusPoint Capital Management, LP | 0 | $0 | 0.00% | −393,586−100.0% | Sold out |
| Sphera Funds Management Ltd. | 0 | $0 | 0.00% | −118,103−100.0% | Sold out |
| Acadian Asset Management LLC | 0 | $0 | 0.00% | −110,835−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −38,911−100.0% | Sold out |
| EntryPoint Capital, LLC | 0 | $0 | 0.00% | −33,219−100.0% | Sold out |
| Bridgeway Capital Management, LLC | 0 | $0 | 0.00% | −25,000−100.0% | Sold out |
| UBS Asset Management Americas Inc | 0 | $0 | 0.00% | −24,100−100.0% | Sold out |
| Cornercap Investment Counsel Inc | 0 | $0 | 0.00% | −19,236−100.0% | Sold out |
| Meeder Asset Management Inc | 0 | $0 | 0.00% | −10,050−100.0% | Sold out |
| STRS Ohio | 0 | $0 | 0.00% | −3,100−100.0% | Sold out |
| Capital Performance Advisors LLP | 0 | $0 | 0.00% | −29−100.0% | Sold out |